Rentschler Biopharma

Rentschler Biopharma

Biotechnologieforschung

Laupheim, Baden-Württemberg 26.060 Follower:innen

Advancing medicine to save lives. Together.

Info

Rentschler Biopharma is a leading contract development and manufacturing organization (CDMO) focused on the process development and manufacturing of biopharmaceuticals in mammalian cell lines. We provide an essential contribution to the availability of biopharmaceuticals and thereby help millions of people. Founded in 1927, Rentschler is a family-owned company, located in Laupheim, Germany and employing around 700 people. As a full-service CDMO we support our global clients through to market approval of their products. The company’s clients include innovative biotech companies and major pharmaceutical companies around the world. Many years of experience and excellence in finding solutions as well as certified quality management and advanced technologies ensure Rentschler’s high quality standards. The drive to develop novel effective solutions is deeply rooted in the Rentschler DNA. We are constantly evolving. This enables us to react quickly and effectively even to the most demanding client requirements. What unites us at Rentschler Biopharma, is the passion for what we do. It is the fundamental basis for superior quality - and the drive within our entire process chain. Our corporate culture is characterized by a sense of responsibility, mutual respect and an open, communicative nature. This enables fast, efficient decisions and guarantees smooth-running processes.

Branche
Biotechnologieforschung
Größe
1.001–5.000 Beschäftigte
Hauptsitz
Laupheim, Baden-Württemberg
Art
Privatunternehmen
Gegründet
1927
Spezialgebiete
Contract Development and Manufacturing of Biopharmaceuticals, Regulatory Support, Analytics and Quality Control, Cell Line Development, Process Development, Formulation Development, Biomanufacturing, Mammalian cells, Commercial supply, Consulting, Cell and gene therapy, advanced therapies und viral vectors

Orte

Beschäftigte von Rentschler Biopharma

Updates

  • Unternehmensseite von Rentschler Biopharma anzeigen, Grafik

    26.060 Follower:innen

    We are delighted to join our COO, Christiane Bardroff, in congratulating this year's graduates from the Hochschule für angewandte Wissenschaften Kempten (Kempten University of Applied Sciences).

    Profil von Christiane Bardroff anzeigen, Grafik

    Chief Operating Officer (COO)

    What an inspiring day at the University of Kempten's graduation ceremony on October 25th, where about 1,000 graduates were celebrated. It was my privilege to give the keynote speech on this special occasion with approximately 1,700 guests in attendance. I spoke about the "butterfly effect" (small things can make the world change) that I have experienced in exciting ways throughout my career and that the “how” is even more important than the “what”. Working with amazing, collaborative teams, I have been able to contribute to tomorrow's medicine by being involved in the development, production and launch of many biopharmaceuticals. But there is more to making an impact: At the family-owned company Rentschler Biopharma, the "how" is even more important than the "what". I’ve found that small changes can make a big difference, just like the butterfly effect. A kind gesture or an inspiring word is often worth so much at the end of the chain when large teams work together. A bold "Yes!", a courageous decision or a principled approach always has the potential to create huge positive change...even more so when you are committed to making the world a better place. Yes, it is the “how” that´s so important. I also encouraged the audience that we need to collaborate everywhere in our world and build bridges wherever possible: between cultures, disciplines and ideologies. In a world full of bridges, it is much more inspiring to take responsibility - no matter where you are in your career. Congratulations again to all the graduates! The world deserves you – unfold your impact in it!

  • Unternehmensseite von Rentschler Biopharma anzeigen, Grafik

    26.060 Follower:innen

    Discover a new era of process development solutions with our new Rentschler Development Services! With our tailored offerings – Velocity, Flexibility and Liberty – we provide fast-track, flexible and creative solutions to meet your project’s unique needs at every stage of development. Ready to accelerate your project’s potential? Then visit our website https://lnkd.in/ebmxwFnc Our Business Development Team, Federico Pollano, Patrick Meyer, Konstantin Bagnjuk, Dr. Susanne Gulden and Katarzyna Tkocz, are looking forward to helping you find the best-fit solution for your endeavor. Meet them at Bio-Europe in Stockholm from November 4-6 or get in touch directly via our website. 

  • Unternehmensseite von Rentschler Biopharma anzeigen, Grafik

    26.060 Follower:innen

    Discover how we support our clients in fast-track biopharma development in our latest white paper: "Fast Path to Market: Going from GMP1 to PPQ in Just 12 Months”, by Jessica Feldman, PhD Feldman, our Director of Process Science in Milford, and Henning Gerschewski, our Vice President, Manufacturing Science and Technology in Laupheim.     This white paper dives into a case study, exploring how to achieve:    ▷ Rapid process optimization to ensure product scalability and quality  ▷ Seamless collaboration across our sites in the U.S. and Europe to enhance process efficiency  ▷ Regulatory excellence throughout the PPQ process    Download the full white paper here to see how we support faster paths to market. You can download the white paper here: https://lnkd.in/ezX6gG7j    #RentschlerBiopharma #ReliabilityYouCanTrust #Whitepaper 

  • Unternehmensseite von Rentschler Biopharma anzeigen, Grafik

    26.060 Follower:innen

    Christiane Bardroff, our COO, was recently featured in Contract Pharma, where she shared key insights on the company's latest strategic investments and the evolving biopharma landscape.     This year, we significantly expanded our global cGMP capacity with the addition of a new production line at our Milford, MA facility, marking one of the largest investments in our company's history. We also continue to advance in cell and gene therapy with expanded capabilities at our Stevenage, UK site, including new lentiviral vector manufacturing services.   In the interview, Christiane addresses major industry trends, such as the rise of precision medicine and navigating geopolitical challenges.      Read the full interview here: https://lnkd.in/ec_nAY-4

    • Kein Alt-Text für dieses Bild vorhanden
  • Unternehmensseite von Rentschler Biopharma anzeigen, Grafik

    26.060 Follower:innen

    We are thrilled to announce that we have been awarded the prestigious EcoVadis Silver Medal, placing us among the top 15 percent of companies assessed by EcoVadis in the past 12 months.     This independent rating is based on a comprehensive set of Environment, Labor and Human Rights, Ethics, and Sustainable Procurement criteria. We are happy to be specifically placed in the top 7 percent of companies rated by EcoVadis in the “Manufacture of basic pharmaceutical products” industry and have significantly improved our score compared to last year’s evaluation.     Since its foundation in 2007, EcoVadis has grown to become the world’s largest and most trusted provider of business sustainability ratings, creating a global network of more than 130,000+ rated companies.      This result is a great endorsement of our commitment to advancing sustainable practices across our operations, and another step on our journey to creating value sustainably. Thank you to our teams and stakeholders for their contributions to this success.     Learn more about our sustainability initiatives here: https://lnkd.in/e5ifngBu     #RentschlerBiopharma #CDMO #ecovadis #sustainability 

    • Kein Alt-Text für dieses Bild vorhanden
  • Unternehmensseite von Rentschler Biopharma anzeigen, Grafik

    26.060 Follower:innen

    Did you know that this year we are celebrating 30 years of BIO-Europe? We look forward to seeing you in Stockholm from 4-6 November!       Come and meet our team of experts at booth number 47. With over 50 years of experience in complex biopharmaceuticals, we provide integrated CDMO services to meet your unique needs. Benedikt von Braunmühl, our CEO, Federico Pollano, Konstantin Bagnjuk, Dr. Latika Bhonsle-Deeng, Dr. Susanne Gulden and Katarzyna Tkocz look forward to sharing insights on our service offerings for complex modalities and advanced therapies to discuss your project requirements.     Partnering is already well underway. Connect with us through BIO's One-on-One Partnering System and discover why we're your trusted CDMO partner for biopharmaceutical solutions with reliability you can trust: https://lnkd.in/ePZckDw3    #RentschlerBiopharma #CDMO #BIOEurope 

    • Kein Alt-Text für dieses Bild vorhanden
  • Unternehmensseite von Rentschler Biopharma anzeigen, Grafik

    26.060 Follower:innen

    We are pleased to announce the largest single investment in our headquarters in Laupheim, Germany – the construction of a new, state-of-the-art buffer media facility, set to be operational by 2028.  Benedikt von Braunmühl, our CEO, commented: “This investment underscores our commitment to the long-term development of our Laupheim site, a key part of Germany’s biotechnology landscape. This expansion will strengthen our competitive position in one of the world’s fastest-growing industries. As a company with 150 years of tradition, Rentschler Biopharma has always embraced forward-looking, strategic planning, enabling us to grow sustainably as an independent family-owned company. I would like to thank all colleagues involved in the planning and execution of this significant project. Government support for a German national pharmaceutical strategy is an important signal for the industry as a whole. While our focus remains on strengthening global partnerships, this investment in our German site plays a crucial role in ensuring supply chain reliability and advancing our long-term growth strategy." Christiane Bardroff, our COO, added: “As a CDMO, it is our responsibility to support our clients in transforming innovative ideas into life-saving biopharmaceuticals. Patients with rare and severe diseases rely on the therapies we develop and manufacture in partnership with our clients. This project is therefore not just an investment in our infrastructure, it is a fundamental part of our work, creating value sustainably for the benefit of our clients and for patients and ensuring the availability of therapeutics in Germany and globally. With the new buffer media station, we are making a significant contribution to operational excellence, enabling us to respond rapidly to growing client demands. We are also creating a more ergonomic work environment for our employees and positioning our site for future success.” Read the press release here: https://lnkd.in/e7iA6XU5

    • Kein Alt-Text für dieses Bild vorhanden
  • Unternehmensseite von Rentschler Biopharma anzeigen, Grafik

    26.060 Follower:innen

    Day 1 at the ESGCT conference in Rome, Italy! Don’t miss our poster presentation this evening at 19:30 local time. Christopher Perry, our Downstream Processing Team Lead, will be sharing insights on the stepwise approach we’ve developed to achieve AAV full capsid enrichment. Make sure to check out poster #P0035.    Our onsite team, Nathan Sweeney and Bertille Boudier is looking forward to connecting with everyone there and discussing your upcoming advanced therapy programs.     Learn more about our advanced therapy capabilities here: https://lnkd.in/eHuE5B9j   #RentschlerBiopharma #AdvanceTherapies #ESGCT2024 #cellandgenetherapy #CGT

  • Unternehmensseite von Rentschler Biopharma anzeigen, Grafik

    26.060 Follower:innen

    Benedikt von Braunmühl, our CEO, recently spoke to European Biotechnology about our company's development and future direction. If you are interested in learning more about how we are empowering tomorrow's therapies today, the interview is well worth a read!   You can find the interview here: https://lnkd.in/ejYGBeTZ European Biotechnology - Life Science and Industry Magazine (EBM) https://lnkd.in/eqB-gZaw

Ähnliche Seiten

Jobs durchsuchen